Biotech Startups

Leucine offers AI Investigator, a quality management platform that automates root cause analysis and provides data-driven corrective action recommendations for manufacturing and quality assurance teams.

3 investors

Level Nine develops nanozyme technology that combines enzymes with nanotechnology to create catalysts for green chemistry and the green chemicals industry.

3 investors

LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.

3 investors

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization. The company serves patients with immunological disorders and rare genetic conditions.

3 investors

Ligand is a royalty aggregator that finances late-stage clinical development and commercialization programs for biopharmaceutical companies. The company maintains a diversified portfolio of royalty assets across oncology, rare diseases, and other therapeutic areas, and licenses proprietary technology platforms to pharmaceutical manufacturers.

3 investors

Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale. The platform serves researchers and therapeutics developers studying functional biology for applications in antibody discovery, cellular therapies, and immunotherapy development.

3 investors

LighthouseAI provides solutions for drug supply chain regulation and compliance, serving pharmaceutical companies and supply chain partners.

3 investors

Lime Therapeutics is a biotechnology company developing lipid-altering medicines for cancer, cardiometabolic diseases, lysosomal storage diseases, and neurodegenerative disorders. The company uses LipidSense, a proprietary ultrasensitive lipid detection platform, to discover and develop therapeutics targeting lipid dysfunction.

3 investors

Limula develops an automated, closed platform for manufacturing personalized cell and gene therapies, aiming to move production from open, manual methods to scalable automated processes. It serves cell therapy developers and manufacturers in the biotech and pharmaceutical industry, and is based in Switzerland.

3 investors

Liquidia develops and commercializes inhaled and injectable therapies for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company sells YUTREPIA, an inhaled dry-powder formulation of treprostinil approved by the FDA in May 2025, and shares profits from a generic treprostinil injection marketed by Sandoz, while advancing a pipeline of investigational formulations targeting additional respiratory and vascular diseases.

3 investors

Locksmith Bio applies physics-based AI models to characterise intrinsically disordered regions of proteins and identify potential binding sites within them. Its output is intended for biopharma research teams working on early-stage discovery programmes against targets that conventional approaches have not addressed.

3 investors

Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders. It uses a technology platform combining robotics, automated biobanking, AI-driven cocktail prediction, and synthetic biology, and operates a cGMP viral vector manufacturing facility for clinical trial material.

3 investors

LogicBio is a biotechnology company focused on research and development of treatments for rare diseases, investigating new targets, modalities, and technologies for patients and their families worldwide.

3 investors

LogicInk develops wearable biochemical sensors that detect environmental and personal health signals—such as UV exposure, air quality, and microbiome changes—to provide real-time wellness feedback. The platform allows users to monitor conditions impacting physical and mental health through customizable, worn sensors that integrate daily health awareness with dynamic environmental data.

3 investors

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research. Founded in 2019 out of the Dementia Discovery Fund, it operates in the biotech and therapeutics sector.

3 investors

LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction. The company works in the biopharmaceutical field, building a platform based on its proprietary iMIT mitochondria technology.

3 investors

Lucerna Dynamics provides software that identifies injection errors in nuclear medicine procedures, evaluates their impact, and helps reduce error frequency for healthcare teams.

3 investors

Lumira Ventures is a venture capital firm that invests in biotherapeutic and medical device companies developing innovative therapeutic solutions for patients. The firm focuses on companies creating disruptive treatments, addressing unmet medical needs, improving outcomes, and reducing healthcare costs.

3 investors

Lunaphore develops spatial biology solutions that enable scientists and clinicians to analyze tissue structure and cellular composition. The company was acquired by Bio-Techne in 2023 to expand the combined entity's capabilities in applied spatial biology.

3 investors

Lupeng Pharmaceutical develops next-generation small-molecule targeted drugs for malignant tumors and autoimmune diseases, focusing on hematologic cancer targets such as BTK, Bcl-2, and Bcl-xL, with multi-center clinical development and commercialization in international and Chinese markets. Its lead drug rocbrutinib (Lukeda) has received NMPA approval for market in China.

3 investors

Lutris Pharma develops targeted skin protection treatments for cancer patients, combining clinicians and scientists with oncology expertise. The company focuses on pharmaceutical development in the oncology and dermatology space.

3 investors

Luyef develops precision fermentation and cell-based technologies to produce animal-derived products for food, biomedicine, and cosmetics without factory farming or environmental impact. The company targets industries seeking sustainable, ethical, and cost-effective alternatives to conventional animal-based materials.

3 investors

Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology. The company operates an integrated pipeline spanning discovery through manufacturing and clinical trials, with its own manufacturing facility in Washington.

3 investors

Lynk Pharma develops pharmaceutical products for rheumatoid arthritis and ankylosing spondylitis, with selective licensing arrangements for regional commercialization.

3 investors